Connor, Clark & Lunn Investment Management (CC&L)’s Aclaris Therapeutics ACRS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q2
$1.13M Sell
2025
Q1
$1.32M Sell
2024
Q4
$2.25M Buy
2024
Q3
$382K Buy
2024
Q2
$127K Buy
2024
Q1
$125K Buy
2023
Q4
Sell
2023
Q3
$1.38M Sell
2023
Q2
$2.19M Buy
2023
Q1
$1.43M Buy
2022
Q4
$265K Sell
2022
Q3
$423K Buy
2020
Q4
Sell
2020
Q3
$81K Buy